Allison M. Wilkin

Allison M. Wilkin

Auto-generated profile, based on publicly available information

Allison M. Wilkin

Ottawa Hospital Research Institute, Ottawa ON, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Vaccine
Verified
Journal Article
Open access
SBSita Bhella
Sita Bhella
AWAllison M. Wilkin
Allison M. Wilkin
KHKatrina Hueniken
Katrina Hueniken
AVAbi Vijenthira
Abi Vijenthira
MSMichael Sebag
Michael Sebag
CBC. Arianne Buchan
C. Arianne Buchan
Immune response to COVID-19 vaccine is diminished in patients with hematologic malignancy. There is limited data regarding response to vaccine doses in these patients. To quantify the humoral immune response engendered by 4th and subsequent doses of SARS-CoV-2 vaccination as measured by anti-Spike (anti-S) antibody levels, based on dried blood spot (DBS) testing, in patients with hematologic malignancies. Anti-S binds to the spike protein of the SARS-CoV-2 virus and is indicative of vaccine immunogenicity. We conducted a prospective study of hematologic malignancies between August 2021 and January 2023 at 12 sites across Canada. Participants were followed longitudinally and submitted finger-prick DBS cards at set intervals associated with vaccination. Samples were processed via high throughput ELISA assay to detect serum antibodies against nucleocapsid (N) and spike (S) proteins. We obtained 3071 samples on 790 unique patients. Of these, 372 unique participants with 1840 samples had anti-S results available post-4th, 5th or 6th COVID-19 vaccine dose and were included for analysis. Three hundred thirty-three patients of the 372 participants submitted a DBS sample post 4th dose. Of these, 257 patients (77.2%) had a positive anti-S antibody. A total of 198 patients had paired samples pre- and post-dose 4, of which 59 (29.7%) had a negative anti-S antibody pre-dose 4. Of these, 20 (33.4%) developed positive anti-S antibody post-dose 4. One hundred forty-nine patients submitted a DBS sample post-dose 5. Of these, 135 patients (90.6%) had positive anti-S antibody. A total of 52 had paired samples pre- and post-dose 5. Six (8.7%) had a negative anti-S antibody pre-dose 5, of which two (33.3%) developed positive anti-S antibody post-dose 5. Of these 372 patients, 123 (34%) reported COVID-19 infection and 4 (1%) had a COVID-19 related hospitalization. There were no reported deaths from COVID-19. This prospective cohort study showed that humoral immune response improved with subsequent doses of COVID-19 vaccines.

8 November 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
CBC. Arianne Buchan
C. Arianne Buchan
GAGerard Agbayani
Gerard Agbayani
KHKatrina Hueniken
Katrina Hueniken
AVAbi Vijenthira
Abi Vijenthira
MSMichael Sebag
Michael Sebag
SBSita Bhella
Sita Bhella